People in the earliest stages of Alzheimer’s disease experience declining cognitive and functional abilities, making it harder for them to remember things and places, carry out simple calculations, use a phone/computer, drive, and adhere to medications. The goal of the RADAR-AD platform is to develop a digital platform that would draw on smartphone, wearable and home-based digital technologies to track subtle changes in the cognitive and functional abilities of people with Alzheimer’s disease. The project will adapt the existing RADAR-CNS project’s platform for Alzheimer’s disease. Among other things, the team will have to take account of the fact that many people with Alzheimer’s disease are older and so may be less familiar with technology, while their condition may make it more difficult for them to learn to handle technological devices. People with Alzheimer’s disease will be fundamentally involved in the design and development of the project so that the systems put in place are acceptable and appropriate for them. The platform will be tested in a clinical study with people with different stages of Alzheimer’s disease. Ultimately, the project results will make it easier to assess how well new dementia treatments work.
RADAR-AD
FACTS & FIGURES
| Start Date |
|
| End Date |
|
| Call |
IMI2 - Call 12
|
| Grant agreement number |
806999
|
Type of Action:
| Contributions | € |
|---|---|
| IMI Funding |
4 999 757
|
| EFPIA in kind |
2 327 402
|
| Associated Partners |
223 132
|
| Other |
89 854
|
| Total Cost |
7 640 145
|
Summary
Achievements & News
Data-driven personalised care for Alzheimer's patients
October 2019
Approximately 50 million people worldwide live with dementia, a figure the World Health Organization predicts will triple to 152 million by 2050. By 2030, the global cost of dementia could reach more than USD 2 trillion. To improve the lives of those patients and reduce the associated costs, IMI’s RADAR-AD project is working on using detailed information about the health of each patient to transition from a ‘diagnose and treat’ to a ‘predict and pre-empt’ model of care.###
RADAR-AD is combining mobile and smart home devices with data analytics technologies to provide enhanced care and remote health monitoring for patients with Alzheimer’s disease (AD) at all stages of disease progression.
‘RADAR-AD gives patients the opportunity to be better informed about their own health status and to use this information to self-manage the disease. This will ultimately help personalise care for each patient and allow them to live independently for longer,’ says project coordinator Dag Årsland at King's College London. ‘In parallel, we anticipate that the platform will improve our understanding of Alzheimer’s disease subtypes and progression, supporting the development of new and more effective treatments.’
Participants Show participants on map
EFPIA companies
- Eli Lilly and Company Limited, Basingstoke, United Kingdom
- Janssen Pharmaceutica Nv, Beerse, Belgium
- Novartis Pharma AG, Basel, Switzerland
- Takeda Development Centre Europe LTD, London, United Kingdom
Universities, research organisations, public bodies, non-profit groups
- Agentschap College Ter Beoordeling Van Geneesmiddelen, Utrecht, Netherlands
- Ethniko Kentro Erevnas Kai Technologikis Anaptyxis, Thermi Thessaloniki, Greece
- Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany
- Karolinska Institutet, Stockholm, Sweden
- King'S College London, London, United Kingdom
- Stichting Vumc, Amsterdam, Netherlands
- University of Oxford, Oxford, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- Altoida AG, Luzern, Switzerland
- Stichting Lygature, Utrecht, Netherlands
- The Hyve BV, Utrecht, Netherlands
Patient organisations
- Alzheimer Europe, Luxembourg, Luxembourg
Associated partners
- Software AG, Darmstadt, Germany
| Participants | |
|---|---|
| Name | IMI funding in € |
| Agentschap College Ter Beoordeling Van Geneesmiddelen | 50 000 |
| Alzheimer Europe | 230 500 |
| Ethniko Kentro Erevnas Kai Technologikis Anaptyxis | 266 250 |
| Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | 231 250 |
| Karolinska Institutet | 100 171 |
| King'S College London | 885 655 |
| Stichting Lygature | 551 306 |
| Stichting Vumc | 1 335 127 |
| The Hyve BV | 352 353 |
| University of Oxford | 997 145 |
| Total Cost | 4 999 757 |
Dag Årsland
King'S College London
LINKS AND DOCUMENTS
Project website
www.radar-ad.org
Twitter
@RADARAD7